ImmusanT's Nexvax2 demonstrates positive outcome in Phase Ib trial to treat coeliac disease

Clinical-stage company ImmusanT's therapeutic vaccine Nexvax2 has demonstrated a positive outcome in the Phase Ib trial for the treatment of coeliac disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news